Terol LA-4 mg Capsule 10s

Uses of Terol LA-4 mg Capsule 10s

Tolterodine reduces muscular spasm of urinary bladder neck and thereby relaxes neck. It helps in smooth passage of urination which was obstructed due to muscle spasm of bladder neck.

Side Effects of Terol LA-4 mg Capsule 10s

Dry mouth, chest pain, headache, somnolence, fatigue, dry skin, abdominal pain, constipation, dyspepsia, diarrhoea, dizziness, anxiety, wt gain, abnormal vision, dry eyes, paraesthesia, nervousness, urinary retention.

Drug Interactions

Increased risk of overdosage with potent CYP3A4 inhibitors e.g. macrolide antibiotics (erythromycin and clarithromycin), azole antifungals (e.g. ketoconazole and itraconazole), protease inhibitors, ciclosporin or vinblastine. Increased risk of torsade de pointes with drugs that prolong the QT interval (e.g. class Ia and class III antiarrhythmics). Increased risk of 'cholinergic neurogenic hypersensitivity' with centrally acting anticholinesterases (e.g. donepezil, rivastigmine). Increased risk of antimuscarinic side effects with antimuscarinic drugs.

Contraindications

Severe ulcerative colitis, toxic megacolon, urinary retention, gastric retention, myasthenia gravis, uncontrolled narrow-angle glaucoma, pregnancy.

Mechanism of Action

Tolterodine is a competitive muscarinic receptor antagonist with actions similar to atropine. It is used in the management of urge urinary incontinence, urgency and frequency. Absorption: Peak plasma concentration in 1-3 hr. Absolute bioavailability: 17%; 65% (poor metabolisers). Distribution: Protein-binding: Extensive (mainly to α1-acid glycoprotein). Half-life: 2-3 hr; 10 hr (poor metabolisers). Metabolism: Metabolised mainly in the liver by the CYP2D6 to active 5-hydroxymethyl tolterodine (in extensive metabolisers accounting for majority of population). Poor metabolisers, accounting for 7% of population: Metabolised via CYP3A4 to inactive N-dealkylated metabolites. Clinical use not affected by metabolism differences as tolterodine and its CYP2D6-dependent metabolite, 5-hydroxymethyl tolterodine are equipotent. Excretion: Excreted in the urine, mainly as metabolites and some as unchanged drug (<1%) and via faeces (17% ).

Special Precautions

Bladder flow obstruction, GI obstructive disorders, renal or hepatic impairment, autonomic neuropathy, hiatus hernia, risk of decreased GI motility, patients at risk of QT interval prolongation (e.g. electrolyte disturbances, bradycardia, pre-exisiting cardiac disorder).

How to Use

Take orally with food and water, as directed by your physician.

How to Store

Keep in a cool, dry place away from sunlight and moisture.

Safety Concerns

• Alcohol: Avoid during treatment.
• Breastfeeding: Not recommended.
• Pregnancy: Contraindicated.
• Liver/Kidney: Use with caution.

Content Disclaimer

This content is for educational purposes only. Please consult your doctor before use.